Chronic caffeine treatment reverses memory impairment and the expression of brain BNDF and TrkB in the PS1/APP double transgenic mouse model of Alzheimer's disease

Mol Med Rep. 2013 Sep;8(3):737-40. doi: 10.3892/mmr.2013.1601. Epub 2013 Jul 25.

Abstract

The objective of this study was to investigate the effects of varying doses of caffeine on memory impairment and the expression of brain neurotrophic derived factor (BNDF) and TrkB in PS1/APP double transgenic mouse models. PS1/APP double transgenic mice were administered 0.3 ml/day of saline, 1.5 mg/day of caffeine or 0.75 mg/day of caffeine for eight weeks. A water maze test and western blotting were used to determine the memory capability and expression of hippocampal BNDF and TrkB of the mice. The results demonstrated that 0.75 mg/day and 1.5 mg/day doses of caffeine significantly increased memory capability and the expression of hippocampal BDNF and TrkB in PS1/APP mice with a dose-response effect. The results suggested that chronic caffeine treatment may reverse memory impairment in PS1/APP transgenic mice, and BDNF and its receptor TrkB, may be involved in this process.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Amyloid beta-Protein Precursor / deficiency
  • Amyloid beta-Protein Precursor / genetics
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Behavior, Animal / drug effects
  • Brain-Derived Neurotrophic Factor / metabolism*
  • Caffeine / pharmacology*
  • Caffeine / therapeutic use
  • Disease Models, Animal
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Memory / drug effects*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Presenilin-1 / deficiency
  • Presenilin-1 / genetics
  • Presenilin-1 / metabolism
  • Receptor, trkB / metabolism*

Substances

  • Amyloid beta-Protein Precursor
  • Brain-Derived Neurotrophic Factor
  • Presenilin-1
  • Caffeine
  • Receptor, trkB